БХАКТА Сунил (US),ХАЗЕН Мередит (US),ХОНГО Джо-Энн С. (US),ДЖУНУТУЛА Джагат Р. (US),ХОТЗЕЛ Исидро (US),ШАН Юнлэй (US),ЮЙ Шан-Фань (US)
申请号：
RU2014145633
公开号：
RU2014145633A
申请日:
2013.03.14
申请国别(地区):
RU
年份:
2016
代理人:
摘要：
1. An isolated antibody comprising at least one CDR sequence selected from the group consisting of: (a) CDR-L1 sequence of any of SEQ ID NO: 4-10 (b) CDR-L2 sequence of any of SEQ ID NO: 11-16 (c) CDR-L3 sequence of any of SEQ ID NO: 17-24 (d) CDR-H1 sequence of any of SEQ ID NO: 25-32 or 67 (e) CDR-H2 sequence of any of SEQ ID NO: 33-40 or 68 and (f) CDR-H3 sequence of any of SEQ ID NO: 41-48 or 69-73.2. An isolated antibody sequence comprising VH and VL sequence, wherein said VL sequence is a sequence of any listed in SEQ ID NO: 49-57, or 74.3. A cell that produces the antibody according to para. 1.4. An isolated nucleic acid which encodes an antibody according to para. 1.5. A method of identifying a first antibody that binds to TAT194 antigenic epitope bound by a second antibody wherein said second antibody is an antibody according to Claim. 1, wherein said method comprises determining the ability of said first antibody to block binding of said second antibody to TAT194 polypeptide, wherein the ability of said first antibody to block binding of said second antibody to said TAT194 polypeptide of at least 40% and at equal antibody concentrations yk indicates the card the ability of said first antibody to bind to an epitope bound by said second antitelom.6. A method of inhibiting growth of a cell, which expresses TAT194 polypeptide, said method comprising contacting said cell with an antibody according to Claim. 1, wherein the binding of said antibody to said TAT194 polypeptide causes inhibition of the growth of said kletki.7. A method for therapeutically treating a mammal having a cancerous tumor, including1. Выделенное антитело, включающее, по меньшей мере, одну CDR последовательность, выбранную из группы, состоящей из:(a) CDR-L1 последовательности любого из SEQ ID NO:4-10(b) CDR-L2 последовательности любого из SEQ ID NO:11-16(c) CDR-L3 последовательности любого из SEQ ID NO: 17-24(d) CDR-H1 последовательности любого из SEQ ID NO:25-32 или 67(e) CDR-H2 последовате
